Fig. 6: Long-chain alkyl-TPP molecules ablate the competitive advantage of mouse and human Dnmt3a-mutant HSPCs and their progeny.

A Experimental design. B Number of myeloid CFU in secondary plating of control and Dnmt3a^R878H/+ BM cells. Bars represent mean ± SEM, points from biological replicate mice (n = 5 control veh, n = 5 control +MitoQ, n = 6 R878H/+ veh, n = 6 R878H/+ +MitoQ). Statistical analysis used one-way ANOVA with Sidak’s multiple comparisons test. C Experimental design. D Number of myeloid CFU in secondary plating of control and Dnmt3a^R878H/+ BM cells. Bars represent mean ± SEM, points from biological replicate mice (n = 3). Statistical analysis used one-way ANOVA with Sidak’s multiple comparisons test. E Experimental design. F Frequency of donor-derived tdTomato⁺ CD45.2⁺ cells in PB, BM and HSPCs of control and Dnmt3a^R878H/+ recipient mice after treatment with MitoQ. Bars represent mean ± SEM, points from biological replicate mice (n = 11 control veh, n = 5 control +MitoQ, n = 10 R878H/+ veh, n = 5 R878H/+ +MitoQ). The transplant was performed 3 independent times. Statistical analysis used two-way ANOVA with Fisher’s LSD test. G Experimental design. H Frequency of DNMT3A-knockdown human CD34+ cells after 14 days of MitoQ treatment. Bars represent mean ± SEM, points are from one human sample with technical replicates (n = 6). Statistical analysis used two-way ANOVA with Tukey’s multiple comparisons test. Source data are provided as a Source Data file.